For decades, millions of women have been navigating a complex, multi-system condition under a name that didn’t tell the full story. That’s finally changing.
Polycystic ovary syndrome — widely known as PCOS — has been officially renamed polyendocrine metabolic ovarian syndrome, or PMOS, following a landmark global consensus published in The Lancet in 2026.
Understanding PMOS — and why the old name fell short — can help you advocate for better care, pursue an accurate diagnosis, and make informed decisions about your health.
Why the Name Had to Change
PCOS was named for one of its possible visible characteristics: the appearance of small follicles (often called cysts) on the ovaries. The name implied a narrow, ovarian-focused disorder — when in reality, PCOS is a complex, multi-system condition involving the endocrine, metabolic, reproductive, and psychological systems.
The consequences of this mismatch have been significant. An estimated 70% of women with PMOS remain undiagnosed. Patients were confused about what the condition meant for their health. Clinicians outside of gynecology often didn’t recognize it as relevant to their specialty. Research funding lagged. And women frequently felt dismissed or misunderstood when their symptoms extended far beyond their ovaries.
The renaming effort was 14 years in the making. It involved 56 academic, clinical, and patient organizations, more than 14,000 survey responses from patients and health professionals across the globe, and multiple rounds of international consensus workshops. The result reflects what researchers and patients have long known: this condition deserved a name that matched its reality.
What PMOS Actually Is
PMOS affects an estimated 1 in 8 women of reproductive age — more than 170 million people worldwide. It is driven by a disturbance in the body’s endocrine (hormonal) system, which creates a cascade of effects across multiple systems.
Endocrine: People with PMOS typically have elevated androgen levels (hormones such as testosterone), disrupted neuroendocrine signaling, and abnormal anti-Müllerian hormone (AMH) levels. These hormonal imbalances drive many of the condition’s most visible symptoms.
Metabolic: Insulin resistance is present in the majority of people with PMOS — including up to 75% of lean women with the condition. When the body can’t respond normally to insulin, blood sugar levels rise, the pancreas compensates by producing more insulin, and over time, the risk for type 2 diabetes increases. The metabolic burden of PMOS also includes increased risk for impaired glucose tolerance, high cholesterol, high blood pressure, fatty liver disease, and cardiovascular disease.
Ovarian Dysfunction: Disruptions in follicle development, ovulation, and reproductive hormones. Irregular periods, difficulty ovulating, and fertility challenges are common experiences for people with PMOS.
Other associated features include acne, hair thinning or loss (female-pattern), excess body hair (hirsutism), sleep apnea, depression, anxiety, and body dysmorphia.
Why "Polyendocrine Metabolic Ovarian" Is More Accurate
The new name was chosen because it captures what is actually happening in the body:
- Polyendocrine reflects that multiple hormonal systems are involved — not just the ovaries, but also insulin signaling, adrenal androgens, and neuroendocrine pathways.
- Metabolic acknowledges the significant and well-documented metabolic risks that affect most people with this condition.
- Ovarian retains the ovarian component, which is a genuine and defining feature — just no longer reduced to the misleading implication of pathological cysts.
The word “polycystic” has been deliberately removed. It caused decades of confusion, leading patients to believe they had large cysts that needed to be treated, when in fact the ultrasound appearance simply accumulated small follicles resulting from disrupted ovulation.
What This Means for Getting Diagnosed
One of the most important goals of the name change is improving the diagnosis rate. With 70% of affected individuals currently going undiagnosed, many women are living with metabolic and hormonal dysfunction that’s going unmanaged — sometimes for years.
Diagnosis in adults currently requires meeting at least two of the following three criteria:
- Irregular or absent ovulation (oligo-anovulation)
- Clinical or biochemical signs of hyperandrogenism (elevated male hormones)
- Polycystic ovarian appearance on ultrasound or elevated AMH levels
Talk to your provider if you experience:
- Irregular menstrual cycles — particularly fewer than 8 periods per year, or cycles lasting longer than 40 days
- Signs of elevated androgens such as persistent acne, hair thinning at the scalp, or excess facial or body hair
- Difficulty conceiving
- Unexplained weight gain, especially around the midsection
- Symptoms of insulin resistance or blood sugar fluctuations
How PMOS Is Treated
Because PMOS affects multiple systems, effective treatment requires addressing the whole picture — not just one symptom in isolation.
Lifestyle interventions remain the first-line recommendation. A balanced diet, regular physical activity, and achieving a healthy weight have all been shown to improve PMOS symptoms, including hormonal balance, insulin sensitivity, and menstrual regularity.
Medications may be used to address specific aspects of the condition. Birth control pills or bioidentical hormones like progesterone are commonly prescribed to regulate menstrual cycles and reduce androgen-related symptoms. GLP-1 medications, metformin, and a supplement called berberine have shown benefit for metabolic and insulin resistance features of PMOS. Fertility treatments can be used to help induce ovulation for those trying to conceive.
Mental health support. Depression, anxiety, and body image concerns are associated features of PMOS — not separate issues, but part of the condition itself.
What the name change reinforces is something Forum Health providers have always understood: effective care for PMOS requires providers who can see the full picture. A dermatologist managing your acne, a gynecologist managing your cycles, and a dietitian advising on nutrition are all addressing pieces of the same condition. Integrated, coordinated care — the kind Forum Health is built around — is what leads to better outcomes.
A Long-Overdue Recognition
The renaming of PCOS to PMOS is a formal acknowledgment of what this condition is: a complex, multi-system disorder with serious long-term health implications that has been historically underdiagnosed, underfunded, and underestimated.
For the women who spent years being told their symptoms were “just hormones” or who were handed a pamphlet and sent home — this change is a step toward being taken seriously.
If you have been diagnosed with PCOS, or suspect you may have PMOS, a Forum Health provider can work with you to evaluate your hormonal and metabolic health comprehensively and build a treatment plan that fits your needs.
Sources: Teede HJ et al. “Polyendocrine metabolic ovarian syndrome.” The Lancet, 2026. World Health Organization data as cited in referenced reporting.
This content is for informational purposes only and is not a substitute for personalized medical advice. Consult a qualified healthcare provider for diagnosis and treatment recommendations.
